ALDEA Pharmaceuticals
ALDEA Pharmaceuticals develops small-molecule modulators of the ALDH family for the treatment of toxic aldehyde-related diseases.
Launch date
Market cap
-
Enterprise valuation
AUD148—223m (Dealroom.co estimates Aug 2014.)
Redwood City California (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
N/A | $4.5m | Debt | |
N/A | $2.0m | Early VC | |
N/A | $11.5m | Series A | |
$24.0m | Series B | ||
Total Funding | AUD58.0m |
Related Content
Recent News about ALDEA Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.